• 出版社/出版日：Mordor Intelligence / 2020年4月20日
|Single User||￥442,000 (USD4,250)||▷ お問い合わせ|
|Team User||￥494,000 (USD4,750)||▷ お問い合わせ|
|Corporate License||￥780,000 (USD7,500)||▷ お問い合わせ|
The Trachoma Treatment Market is expected to register a CAGR of 5.5% during the forecast period. This is attributed to increasing prevalence of trachoma due to rising air pollution, lack of maintenance of personal hygiene by majority of people in underdeveloped countries. Trachoma is an infectious eye disease, which is caused by bacterium chlamydia trachomatis, and as per World Health Organization (WHO) it is a leading cause of blindness and one of 20 neglected tropical diseases that affects one billion of the world’s poorest people. Moreover, poor sanitation such as sharing the used towels and clothes and unhygienic water and food consumption will propel the market growth in underdeveloped countries. In addition, as per World Health Organization (2018), globally, an estimate of 89.1 million people treated with antibiotics for eliminating trachoma which further boost the revenue growth of the market.
Key Market Trends
Oral Route of Administration is Dominating the Market
Oral rout of administration segment is expected to hold a largest market share owing to easy mode of administration with most favored, ease of production, cost effectiveness, flexibility in design of dosage forms and least sterility constraints. As antibiotics are the first line of therapy for the targeted patient pool leading to boost the revenue growth of segment. Antibiotics such as azithromycin and tetracycline are most commonly used for the treatment of trachoma.
Middle East & Africa is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
Middle East & Africa is expected to hold a significant market share in the global trachoma treatment market as it is the most affected region with trachoma cases. As per World Health Organization (WHO), in 2016 an estimate of 247,000 people being treated with surgical treatment for trichiasis and 83 million people were treated with antibiotic therapy. In addition, 142 million people live in trachoma endemic areas and are at risk of trachoma blindness which further propel the revenue growth of this region.
The market studied is moderately competitive and there are several international as well as local companies. Some of the companies which are currently dominating the market are Allergan, Apotex, Pfizer Inc, Teva Pharmaceutical Industries Ltd., Sandoz, Inc. (Novartis AG), Arbor Pharmaceuticals, Inc., Fresenius Kabi AG, Merck & Co., Inc, AbbVie, Inc
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence and Prevalence of Trachoma
4.2.2 Favourable Government Initiative
4.3 Market Restraints
4.3.1 Lack of Awareness
4.3.2 Side Effects
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Route of Administration
5.2 By Drug Class
5.2.3 Ophthalmic anti-infective
5.3.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle-East and Africa
5.3.5 South America
126.96.36.199 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.3 Pfizer Inc.
6.1.4 Teva Pharmaceutical Industries Ltd.
6.1.5 Sandoz, Inc. (Novartis AG),
6.1.6 Arbor Pharmaceuticals, Inc.
6.1.7 Fresenius Kabi AG
6.1.8 Merck & Co., Inc.
6.1.9 AbbVie, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS